ATE147978T1 - Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit - Google Patents

Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Info

Publication number
ATE147978T1
ATE147978T1 AT93909326T AT93909326T ATE147978T1 AT E147978 T1 ATE147978 T1 AT E147978T1 AT 93909326 T AT93909326 T AT 93909326T AT 93909326 T AT93909326 T AT 93909326T AT E147978 T1 ATE147978 T1 AT E147978T1
Authority
AT
Austria
Prior art keywords
fluoroallylamine
fluorophenethyl
alzheimer
disease
treatment
Prior art date
Application number
AT93909326T
Other languages
English (en)
Inventor
Ian A Mcdonald
Michael G Palfreyman
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE147978T1 publication Critical patent/ATE147978T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93909326T 1992-05-27 1993-04-14 Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit ATE147978T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88867192A 1992-05-27 1992-05-27

Publications (1)

Publication Number Publication Date
ATE147978T1 true ATE147978T1 (de) 1997-02-15

Family

ID=25393634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93909326T ATE147978T1 (de) 1992-05-27 1993-04-14 Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit

Country Status (15)

Country Link
EP (1) EP0642338B1 (de)
JP (1) JPH07507299A (de)
KR (1) KR950701518A (de)
AT (1) ATE147978T1 (de)
AU (1) AU672401B2 (de)
CA (1) CA2135752C (de)
DE (1) DE69307702T2 (de)
DK (1) DK0642338T3 (de)
ES (1) ES2101311T3 (de)
GR (1) GR3022608T3 (de)
HU (1) HUT72316A (de)
MX (1) MX9303074A (de)
NO (1) NO944524D0 (de)
WO (1) WO1993024120A1 (de)
ZA (1) ZA933567B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505276A (ja) * 1993-09-24 1997-05-27 メレルファーマスーティカルズ インコーポレイテッド （Ｅ）−２−（ｐ−フルオロフェネチル）−３−フルオロアリルアミンを含有するトランスダーマルデバイス、およびアルツハイマー病の処置に於けるその使用方法
US5599986A (en) * 1994-09-29 1997-02-04 Hoechst Marion Roussel Inc. Process for the preparation of alkali metal salts of diformylamide
US5488188A (en) * 1994-09-29 1996-01-30 Merrell Dow Pharmaceuticals Inc. Process for the preparation of (E)-1-amino-2-(fluoromethylene)-4-(p-fluorophenyl)butane, novel processes for preparing an intermediate thereof, and novel intermediates thereof
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
EP1870097A1 (de) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamidederivate zur Behandlung von kognitiven Störungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ224982A (en) * 1987-06-16 1990-08-28 Merrell Dow Pharma E-2-(p-fluorophenethyl)-3-fluoroallylamine and its pharmaceutical compositions

Also Published As

Publication number Publication date
ZA933567B (en) 1993-12-13
ES2101311T3 (es) 1997-07-01
KR950701518A (ko) 1995-04-28
HU9403384D0 (en) 1995-02-28
MX9303074A (es) 1994-01-31
GR3022608T3 (en) 1997-05-31
EP0642338B1 (de) 1997-01-22
CA2135752A1 (en) 1993-12-09
DK0642338T3 (da) 1997-02-10
NO944524L (no) 1994-11-25
AU672401B2 (en) 1996-10-03
AU3978293A (en) 1993-12-30
JPH07507299A (ja) 1995-08-10
EP0642338A1 (de) 1995-03-15
WO1993024120A1 (en) 1993-12-09
DE69307702D1 (de) 1997-03-06
CA2135752C (en) 1998-07-14
DE69307702T2 (de) 1997-05-28
HUT72316A (en) 1996-04-29
NO944524D0 (no) 1994-11-25

Similar Documents

Publication Publication Date Title
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
FI933946A7 (fi) Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
IT9041503A0 (it) Dispositivo per la cura chirurgica dell'ametropia
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
MY104521A (en) Treatment of depression.
RU94011321A (ru) Способ профилактики и лечения заболеваний кожи
FI952953A7 (fi) Aineita metabolisten luustosairauksien hoitamiseen
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
FI953725A0 (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
KR930703003A (ko) 피부질환치료용 제약 조성물
DK8893D0 (da) Medicament for treatment or prevention of disease